English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

This paper presents a meta-analysis regarding the detection rate (DR) of fluorine-18 ( 18 F)-labeled prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT) in the management of patients with prostate cancer (PCa). Relevant studies regarding 18 F-PSMA PET/CT in the management of PCa published until June 1, 2021, were electronically searched in online databases including EMBASE, PubMed, and Web of Science. The primary outcome was the DR of 18 F-PSMA PET/CT in managing PCa patients, while the secondary outcome was the DR of 18 F-PSMA PET/CT according to Gleason scores and serum prostate-specific antigen (PSA) level. The pooled DR was calculated on a per-patient basis, with pooled odd ratios and 95% confidence intervals (CIs). In total, 17 observational studies evaluating 1019 patients with PCa met the inclusion criteria. The DR of 18 F-PSMA PET/CT was 0.83 (95% CI: 0.78-0.88), in the random-effects model. Subsequently, the analysis of DR of 18 F-PSMA PET/CT in PCa patients using Gleason score (≤7 vs ≥8), showed a significant difference in PCa patients. Based on the above results, the higher Gleason score of PCa patients, the higher DR of 18 F-PSMA PET/CT. The DR of 18 F-PSMA PET/CT in PCa was 0.57 for PSA &lt;0.5 ng ml -1 ; 0.75 for PSA ≥0.5 ng ml -1 and &lt;1.0 ng ml -1 ; 0.93 for PSA ≥1.0 ng ml -1 and &lt;2.0 ng ml -1 ; and 0.95 for PSA ≥2.0 ng ml -1 . Therefore, the significant diagnostic value was found in terms of the DR of 18 F-PSMA PET/CT in managing PCa patients and was associated with Gleason score and serum PSA level.

The performance of 18F-PSMA PET/CT in the detection of prostate cancer: a systematic review and meta-analysis